LIVIVO - Search results -

Search results

Result 1 - 10 of total 64

Search options

Article ; Online: Cystic echinococcosis of the bone.

Monge-Maillo, Begoña / Lopez-Velez, Rogelio

2023 Volume 36, Issue 5, Page(s) 341–347

Abstract: Purpose of review: Cystic echinococcosis (CE) has a wide world distribution causing important morbidity. Osseous involvement is present in less than 4% of the CE cases. Its diagnosis and therapeutic management is full of challenges and low grade of ... ...

Abstract	Purpose of review: Cystic echinococcosis (CE) has a wide world distribution causing important morbidity. Osseous involvement is present in less than 4% of the CE cases. Its diagnosis and therapeutic management is full of challenges and low grade of evidence. Recent findings: The study summarizes literature evidence on the management of osseous CE with particular emphasis on new data regarding diagnosis and treatment. Summary: Clinical presentation of osseous CE depends on the skeletal area affected. Diagnosis is mostly based on radiological findings and serology. Recent advances with qPCR on osseous tissue samples seem to be a good option for diagnosis confirmation. Complete resection of the cystic lesion is the only curative option, but it is usually not possible performing palliative surgery and prolonged albendazole intake in most cases. Radiotherapy could be an option, but experience to date is only based on clinical cases.
MeSH term(s)	Humans ; Echinococcosis/diagnostic imaging ; Echinococcosis/therapy ; Albendazole/therapeutic use
Chemical Substances	Albendazole (F4216019LN)
Language	English
Publishing date	2023-08-18
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	645085-4
ISSN	1473-6527 ; 1535-3877 ; 0951-7375 ; 1355-834X
ISSN (online)	1473-6527 ; 1535-3877
ISSN	0951-7375 ; 1355-834X
DOI	10.1097/QCO.0000000000000951
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2462: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral

Monge-Maillo, Begoña / López-Vélez, Rogelio

Asociación Española de Micología Revista iberoamericana de micología. 2021 Apr., June, v. 38, no. 2

2021

Abstract: A review on the current evidence of the efficacy and security of liposomal amphotericinB (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10mg/kg has shown effectiveness in the ... ...

Abstract	A review on the current evidence of the efficacy and security of liposomal amphotericinB (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10mg/kg has shown effectiveness in the treatment of VL due to Leishmania donovani. In contrast, higher doses of L-AmB (up to 30mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by Leishmania infantum acquired in the Americas and Europe the usual dose of L-AmB is 20-21mg/kg. In HIV co-infected patients the required doses are usually higher, up to 60mg/kg, and if it is administered in a prophylactic schedule after the treatment of VL relapses are reduced. L-AmB has shown synergism with other antiparasitic drugs, especially with paromomycin in the Indian subcontinent and with miltefosin in patients coinfected with HIV in East Africa. Due to its efficacy and safety profile, L-AmB is the first therapeutic option for VL.
Keywords	Leishmania donovani ; Leishmania infantum ; antiparasitic agents ; etiology ; mixed infection ; synergism ; therapeutics ; visceral leishmaniasis ; Eastern Africa ; Europe ; India
Language	English
Dates of publication	2021-04
Size	p. 101-104.
Publishing place	Elsevier España, S.L.U.
Document type	Article
ISSN	1130-1406
DOI	10.1016/j.riam.2021.04.002
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral.

Monge-Maillo, Begoña / López-Vélez, Rogelio

Revista iberoamericana de micologia

2021 Volume 38, Issue 2, Page(s) 101–104

Abstract	A review on the current evidence of the efficacy and security of liposomal amphotericinB (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10mg/kg has shown effectiveness in the treatment of VL due to Leishmania donovani. In contrast, higher doses of L-AmB (up to 30mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by Leishmania infantum acquired in the Americas and Europe the usual dose of L-AmB is 20-21mg/kg. In HIV co-infected patients the required doses are usually higher, up to 60mg/kg, and if it is administered in a prophylactic schedule after the treatment of VL relapses are reduced. L-AmB has shown synergism with other antiparasitic drugs, especially with paromomycin in the Indian subcontinent and with miltefosin in patients coinfected with HIV in East Africa. Due to its efficacy and safety profile, L-AmB is the first therapeutic option for VL.
MeSH term(s)	Antiprotozoal Agents/therapeutic use ; Humans ; Leishmania infantum ; Leishmaniasis/drug therapy ; Leishmaniasis, Visceral/drug therapy ; Liposomes/therapeutic use
Chemical Substances	Antiprotozoal Agents ; Liposomes
Language	English
Publishing date	2021-06-12
Publishing country	Spain
Document type	Journal Article ; Review
ISSN	2173-9188
ISSN (online)	2173-9188
DOI	10.1016/j.riam.2021.04.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Chagas Disease in Europe.

Gonzalez-Sanz, Marta / Crespillo-Andújar, Clara / Chamorro-Tojeiro, Sandra / Monge-Maillo, Begoña / Perez-Molina, Jose A / Norman, Francesca F

Tropical medicine and infectious disease

2023 Volume 8, Issue 12

Abstract: Chagas disease is currently present in many non-endemic countries and remains a neglected tropical disease globally. A review of the literature identified significant gaps and scarcity of updated information from European countries, with most studies ... ...

Abstract	Chagas disease is currently present in many non-endemic countries and remains a neglected tropical disease globally. A review of the literature identified significant gaps and scarcity of updated information from European countries, with most studies reporting data from Spain and Italy. The index of underdiagnosis may be as high as 70%, affecting mainly females of child-bearing age. Standardized screening of fertile, non-pregnant, women from endemic countries and subsequent treatment is considered an essential strategy to control transmission and prevent new cases, yet no uniform legislation for screening risk groups exists. There is heterogeneity in Europe in terms of preventive strategies to avoid transfusion-related transmission of Chagas disease, not necessarily in line with the European directives, with some countries conducting systematic screening for
Language	English
Publishing date	2023-12-01
Publishing country	Switzerland
Document type	Journal Article ; Review
ISSN	2414-6366
ISSN (online)	2414-6366
DOI	10.3390/tropicalmed8120513
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Chagas disease is related to structural changes of the gut microbiota in adults with chronic infection (TRIPOBIOME Study).

Pérez-Molina, José A / Crespillo-Andújar, Clara / Trigo, Elena / Chamorro, Sandra / Arsuaga, Marta / Olavarrieta, Leticia / Navia, Beatriz / Martín, Oihane / Monge-Maillo, Begoña / Norman, Francesca F / Lanza, Val F / Serrano-Villar, Sergio

PLoS neglected tropical diseases

2023 Volume 17, Issue 7, Page(s) e0011490

Abstract: Background: The implications of the gut microbial communities in the immune response against parasites and gut motility could explain the differences in clinical manifestations and treatment responses found in patients with chronic Chagas disease.: ... ...

Abstract	Background: The implications of the gut microbial communities in the immune response against parasites and gut motility could explain the differences in clinical manifestations and treatment responses found in patients with chronic Chagas disease. Methodology/principal findings: In this pilot prospective cross-sectional study, we included 80 participants: 29 with indeterminate CD (ICD), 16 with cardiac CD (CCD), 15 with digestive CD (DCD), and 20 controls without CD. Stool was collected at the baseline visit and faecal microbial community structure DNA was analyzed by whole genome sequencing. We also performed a comprehensive dietary analysis. Ninety per cent (72/80) of subjects were of Bolivian origin with a median age of 47 years (IQR 39-54) and 48.3% (29/60) had received benznidazole treatment. There were no substantial differences in dietary habits between patients with CD and controls. We identified that the presence or absence of CD explained 5% of the observed microbiota variability. Subjects with CD exhibited consistent enrichment of Parabacteroides spp, while for Enterococcus hirae, Lactobacillus buchneri and Megamonas spp, the effect was less clear once excluded the outliers values. Sex, type of visceral involvement and previous treatment with benznidazole did not appear to have a confounding effect on gut microbiota structure. We also found that patients with DCD showed consistent Prevotella spp enrichment. Conclusions: We found a detectable effect of Chagas disease on overall microbiota structure with several potential disease biomarkers, which warrants further research in this field. The analysis of bacterial diversity could prove to be a viable target to improve the prognosis of this prevalent and neglected disease.
MeSH term(s)	Humans ; Adult ; Middle Aged ; Gastrointestinal Microbiome/genetics ; Persistent Infection ; Prospective Studies ; Cross-Sectional Studies ; Chagas Disease/drug therapy
Chemical Substances	benzonidazole (YC42NRJ1ZD)
Language	English
Publishing date	2023-07-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2429704-5
ISSN	1935-2735 ; 1935-2735
ISSN (online)	1935-2735
ISSN	1935-2735
DOI	10.1371/journal.pntd.0011490
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatment Options for Visceral Leishmaniasis and HIV Coinfection.

Monge-Maillo, Begoña / López-Vélez, Rogelio

AIDS reviews

2016 Volume 18, Issue 1, Page(s) 32–43

Abstract: Leishmania and HIV coinfection is a major health problem in more than 35 countries worldwide. The impaired immune function of visceral leishmaniasis/HIV-coinfected patients may: (i) favor the reactivation of latent Leishmania infection; (ii) induce a ... ...

Abstract	Leishmania and HIV coinfection is a major health problem in more than 35 countries worldwide. The impaired immune function of visceral leishmaniasis/HIV-coinfected patients may: (i) favor the reactivation of latent Leishmania infection; (ii) induce a more severe presentation of visceral leishmaniasis; (iii) cause a poorer therapeutic response; and (iv) increase the risk of relapse after treatment. One of the major challenges in the management of visceral leishmaniasis/HIV coinfection is developing an effective drug therapy that not only resolves the first episode of visceral leishmaniasis but also prevents relapse. However, scarce evidence and data are available on the optimal therapy for visceral leishmaniasis/HIV coinfection. In our study we reviewed the efficacy of several drugs currently employed for visceral leishmaniasis in HIV patients and current knowledge of secondary prophylaxis. Additionally, we reviewed a set of ongoing clinical trials that are being performed to evaluate the efficacy of new therapeutic regimens for visceral leishmaniasis in patients with and without HIV. Finally, other therapeutic strategies based on immunotherapy, vaccination, or screening for latent leishmaniasis infection in HIV patients are reviewed. Apart from being potentially useful in clinical practice, the results obtained in our study highlight the need for further research on the management of visceral leishmaniasis/HIV coinfection.
MeSH term(s)	Amphotericin B/therapeutic use ; Antimony Sodium Gluconate/therapeutic use ; Antiprotozoal Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Coinfection ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Infections/prevention & control ; Humans ; Leishmania donovani/drug effects ; Leishmaniasis, Visceral/complications ; Leishmaniasis, Visceral/drug therapy ; Leishmaniasis, Visceral/prevention & control ; Meglumine/therapeutic use ; Organometallic Compounds/therapeutic use ; Phosphorylcholine/analogs & derivatives ; Phosphorylcholine/therapeutic use
Chemical Substances	Antiprotozoal Agents ; Antiviral Agents ; Organometallic Compounds ; liposomal amphotericin B ; Phosphorylcholine (107-73-3) ; miltefosine (53EY29W7EC) ; Meglumine (6HG8UB2MUY) ; meglumine antimoniate (75G4TW236W) ; Amphotericin B (7XU7A7DROE) ; Antimony Sodium Gluconate (V083S0159D)
Language	English
Publishing date	2016-01
Publishing country	Spain
Document type	Journal Article ; Review
ZDB-ID	2086783-9
ISSN	1698-6997 ; 1139-6121
ISSN (online)	1698-6997
ISSN	1139-6121
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5711: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Discovery of circulating miRNAs as biomarkers of chronic Chagas heart disease via a small RNA-Seq approach.

Villar, Silvina R / Herreros-Cabello, Alfonso / Callejas-Hernández, Francisco / Maza, María C / Del Moral-Salmoral, Javier / Gómez-Montes, Mario / Rodríguez-Angulo, Héctor O / Carrillo, Irene / Górgolas, Miguel / Bosch-Nicolau, Pau / Molina, Israel / Pérez-Molina, José A / Monge-Maillo, Begoña / Bottasso, Oscar A / Beloscar, Juan / Pérez, Ana R / Fresno, Manuel / Gironès, Núria

Scientific reports

2024 Volume 14, Issue 1, Page(s) 1187

Abstract: Chagas disease affects approximately 7 million people worldwide in Latin America and is a neglected tropical disease. Twenty to thirty percent of chronically infected patients develop chronic Chagas cardiomyopathy decades after acute infection. ... ...

Abstract	Chagas disease affects approximately 7 million people worldwide in Latin America and is a neglected tropical disease. Twenty to thirty percent of chronically infected patients develop chronic Chagas cardiomyopathy decades after acute infection. Identifying biomarkers of Chagas disease progression is necessary to develop better therapeutic and preventive strategies. Circulating microRNAs are increasingly reliable biomarkers of disease and therapeutic targets. To identify new circulating microRNAs for Chagas disease, we performed exploratory small RNA sequencing from the plasma of patients and performed de novo miRNA prediction, identifying potential new microRNAs. The levels of the new microRNAs temporarily named miR-Contig-1519 and miR-Contig-3244 and microRNAs that are biomarkers for nonchagasic cardiomyopathies, such as miR-148a-3p and miR-224-5p, were validated by quantitative reverse transcription. We found a specific circulating microRNA signature defined by low miR-Contig-3244, miR-Contig-1519, and miR-148a-3 levels but high miR-224-5p levels for patients with chronic Chagas disease. Finally, we predicted in silico that these altered circulating microRNAs could affect the expression of target genes involved in different cellular pathways and biological processes, which we will explore in the future.
MeSH term(s)	Humans ; Circulating MicroRNA ; RNA-Seq ; MicroRNAs/metabolism ; Biomarkers/metabolism ; Chronic Disease ; Heart Diseases ; Chagas Disease/diagnosis ; Chagas Disease/genetics
Chemical Substances	Circulating MicroRNA ; MicroRNAs ; Biomarkers ; MIRN224 microRNA, human
Language	English
Publishing date	2024-01-12
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-51487-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The estimated distribution of autochthonous leishmaniasis by Leishmania infantum in Europe in 2005-2020.

Maia, Carla / Conceição, Cláudia / Pereira, André / Rocha, Rafael / Ortuño, Maria / Muñoz, Clara / Jumakanova, Zarima / Pérez-Cutillas, Pedro / Özbel, Yusuf / Töz, Seray / Baneth, Gad / Monge-Maillo, Begoña / Gasimov, Elkhan / Van der Stede, Yves / Torres, Gregorio / Gossner, Céline M / Berriatua, Eduardo

PLoS neglected tropical diseases

2023 Volume 17, Issue 7, Page(s) e0011497

Abstract: Background: This study describes the spatial and temporal distribution between 2005 and 2020 of human and animal leishmaniasis by Leishmania infantum in European countries reporting autochthonous cases, and highlights potential activities to improve ... ...

Abstract	Background: This study describes the spatial and temporal distribution between 2005 and 2020 of human and animal leishmaniasis by Leishmania infantum in European countries reporting autochthonous cases, and highlights potential activities to improve disease control. Methodology/principal findings: It was based on a review of the scientific literature and data reported by the World Health Organization (WHO), the World Organization for Animal Health (WOAH) and the Ministries of Health, including hospital discharges in some countries. Autochthonous infections were reported in the scientific literature from 22 countries, including 13 and 21 countries reporting human and animal infections, respectively. In contrast, only 17 countries reported autochthonous human leishmaniasis cases to the WHO and 8 countries animal infections to the WOAH. The number of WOAH reported cases were 4,203, comprising 4,183 canine cases and 20 cases in wildlife. Of 8,367 WHO reported human cases, 69% were visceral leishmaniasis cases-of which 94% were autochthonous-and 31% cutaneous leishmaniasis cases-of which 53% were imported and mostly in France. The resulting cumulative incidence per 100,000 population of visceral leishmaniasis between 2005-2020, was highest in Albania (2.15 cases), followed by Montenegro, Malta, Greece, Spain and North Macedonia (0.53-0.42), Italy (0.16), Portugal (0.09) and lower in other endemic countries (0.07-0.002). However, according to hospital discharges, the estimated human leishmaniasis incidence was 0.70 in Italy and visceral leishmaniasis incidences were 0.67 in Spain and 0.41 in Portugal. Conclusions/significance: Overall, there was no evidence of widespread increased incidence of autochthonous human leishmaniasis by L. infantum in European countries. Visceral leishmaniasis incidence followed a decreasing trend in Albania, Italy and Portugal, and peaked in Greece in 2013, 2014 and 2017, and in Spain in 2006-2007 and 2011-2013. Animal and human cutaneous leishmaniasis remain highly underreported. In humans, hospital discharge databases provide the most accurate information on visceral leishmaniasis and may be a valuable indirect source of information to identify hotspots of animal leishmaniasis. Integrated leishmaniasis surveillance and reporting following the One Health approach, needs to be enhanced in order to improve disease control.
MeSH term(s)	Animals ; Dogs ; Humans ; Leishmaniasis, Visceral/epidemiology ; Leishmaniasis, Visceral/veterinary ; Leishmania infantum ; Leishmaniasis/epidemiology ; Europe/epidemiology ; Italy/epidemiology ; Leishmaniasis, Cutaneous ; Dog Diseases/epidemiology
Language	English
Publishing date	2023-07-19
Publishing country	United States
Document type	Review ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2429704-5
ISSN	1935-2735 ; 1935-2735
ISSN (online)	1935-2735
ISSN	1935-2735
DOI	10.1371/journal.pntd.0011497
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rickettsioses imported by travellers and migrants to Spain attended in the +Redivi network, 2009-2020.

Llenas-García, Jara / Cañaveral, Ramiro / Arsuaga, Marta / Monge-Maillo, Begoña / Oliveira-Souto, Inés / Torrús-Tendero, Diego / Rodríguez Guardado, Azucena / Calabuig, Eva / Sánchez-Montalvá, Adrián / Domínguez-Castellano, Ángel / de la Calle-Prieto, Fernando / Pérez-Molina, José A

Journal of travel medicine

2023 Volume 30, Issue 3

Abstract: Background: Rickettsioses are emerging zoonotic diseases with worldwide prevalence, recognized as a cause of imported fever in travellers and migrants. Our objective is to describe the microbiological, clinical and epidemiological characteristics of ... ...

Abstract	Background: Rickettsioses are emerging zoonotic diseases with worldwide prevalence, recognized as a cause of imported fever in travellers and migrants. Our objective is to describe the microbiological, clinical and epidemiological characteristics of imported rickettsioses in travellers and migrants included in a Spanish collaborative network database. Methods: This multicentre retrospective observational study was nested in +Redivi, the Cooperative Network for the Study of Infections Imported by Immigrants and Travellers. We asked collaborating centres for microbiological, clinical and epidemiological data on the rickettsiosis cases from the inception of the network in 2009 to December 2020. Results: Fifty-four cases of imported rickettsioses were included; 35 (64.8%) patients were men, and the median age was 37 years (interquartile range 26, 51.2). Only 7.4% of patients were travellers visiting friends and relatives, and 5.6% were migrants. The most frequent travel destination (38.9%) was South Africa, and 90.7% engaged in a high-risk activity. Twenty-seven patients (50.0%) started presenting symptoms after their return to Spain. The most frequent symptoms were febrile syndrome (55.6%) and cutaneous manifestations (27.8%). Most diagnoses (63.0%) were confirmed by serology. Only a few cases (9.3%) required hospitalization. All participants had a full recovery. Conclusions: Clinicians should suspect rickettsial diseases in travellers coming from high-risk areas, especially Southern Africa, who have engaged in activities in rural areas and natural parks. Doxycycline should be considered in the empiric treatment of imported fever of travellers coming from those areas or who have engaged in high-risk activities. There is a need to improve access to molecular diagnosis of rickettsiosis in Spain.
MeSH term(s)	Male ; Animals ; Humans ; Adult ; Female ; Spain/epidemiology ; Transients and Migrants ; Rickettsia Infections/diagnosis ; Retrospective Studies ; Zoonoses ; Travel
Language	English
Publishing date	2023-04-12
Publishing country	England
Document type	Observational Study ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1212504-0
ISSN	1708-8305 ; 1195-1982
ISSN (online)	1708-8305
ISSN	1195-1982
DOI	10.1093/jtm/taad050
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4120: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Haemoglobinopathies in mobile populations from sub-Saharan Africa.

Norman, Francesca F / Gonzalez-Sanz, Marta / Gullón-Peña, Beatriz / Chamorro-Tojeiro, Sandra / Rosas, Marta / Crespillo-Andujar, Clara / Monge-Maillo, Begoña / Comeche, Belen / Corbacho-Loarte, Maria-Dolores / Arcas, Cristina / Peña, Ignacio / Tenorio, Maria C / Lopez-Vélez, Rogelio / Pérez-Molina, Jose A

Journal of travel medicine

2023 Volume 30, Issue 7

MeSH term(s)	Humans ; Hemoglobinopathies/diagnosis ; Hemoglobinopathies/epidemiology ; Africa South of the Sahara/epidemiology
Language	English
Publishing date	2023-08-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1212504-0
ISSN	1708-8305 ; 1195-1982
ISSN (online)	1708-8305
ISSN	1195-1982
DOI	10.1093/jtm/taad115
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4120: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito